亞洲的整形外科生醫材料市場:2012年

亞洲的整形外科生醫材料市場:2012年 是由出版商Millennium Research Group在2011年12月所出版的。 這份英文市場調查報告書價格從美金5995起跳。

簡介

本報告提供亞洲的整形外科生醫材料市場現況與展望調查分析，治療種類與概要，各國市場背景，主要產品的功能、特徵，新產品概要，臨床實驗趨勢，領導品牌的競爭環境與市場佔有率，各國與各類產品的市場成長預測(∼2016年)等彙整資料，為您概述為以下內容。

摘要整理

第1章 臨床環境

• 背景
• 治療概要
  • 骨頭移植術
  • 玻尿酸關節內注射療法
  • 競爭治療
  • 新的競爭治療、技術
• 各國概要
  • 澳洲
  • 中國
  • 香港
  • 日本
  • 韓國
  • 台灣
    • 人口統計與經濟
    • 醫療制度
    • 法律制度
    • 製造、流通等

第2章 產品

• 概要
• 骨移植片
  • 功能
  • 差異化因素
  • 新的產品
• 玻尿酸關節內注射產品
  • 功能
  • 差異化因素
  • 新的產品

第3章 臨床實驗

• 完成的臨床實驗
• 持續中的臨床實驗

第4章 品牌及競爭分析

• 概要
• 人工骨替代材料市場
• 玻尿酸關節內注射市場
  • 競爭概要
  • 更多的競爭環境
  • 市場佔有率
  • 近幾年的事項等

第5章 整形外科生醫材料市場預測

• 市場概要

第6章 人工骨替代材料市場預測

• 市場概要
• 詳細內容市場概要
  • 各材料
  • 手術各類型
• 澳洲
• 日本
• 韓國

第7章 玻尿酸關節內注射市場預測

• 市場概要
• 詳細內容市場概要
• 澳洲
• 中國
• 日本
• 韓國
• 台灣

附錄

圖表

目錄

The Asia Pacific orthopedic biomaterial market will be primarily driven by the region's aging population that requires greater care and maintenance of their bones and joints. The hyaluronic acid (HA) viscosupplementation segment will be particularly favorably affected by the aging and increasingly physically active demographic and will also be supported by rising awareness of the treatment's benefits among physicians and patients. The market will, however, be limited by price competition and reimbursement challenges. Some of the countries in this market will experience reimbursement cuts for HA viscosupplementation treatments, while these treatments are not covered at all in other countries, which will negatively impact pricing through 2016. The bone graft substitute (BGS) market will be fueled by increasing surgeon and patient awareness of the advantages of these materials over autograft. In addition, the introduction of a new bone morphogenetic protein (BMP) in Australia as well as South Korea will cause a surge in revenues as surgeons adopt these premium-priced products; however, strong cost-consciousness among Asia Pacific regulatory bodies and health care facilities will hinder the growth of the BGS market overall.

This report uses a number of methodologies to gather and present data and analysis. At the outset, a large survey of secondary sources is conducted. These sources act as the basis for the primary research stage, which builds and enhances the quantitative and qualitative attributes of the early research.

Secondary sources include

• Government sources:
  • Securities and Exchange Commission filings
  • Therapeutic Goods Administration
  • Australian Register of Therapeutic Goods
  • U.S. Census Bureau
  • Australian Government Department of Health and Ageing
  • Japan Ministry of Health, Labour and Welfare
  • Australian Institute of Health and Welfare
  • Statistics Bureau of Japan
  • Australian Bureau of Statistics
  • Korean Food and Drug Administration
• Orthopedic biomaterial companies:
  • Annual reports, product brochures, corporate profiles, etc.
• Internal databases and reports:
  • Previous reports on similar/related sources
• General Internet searches, medical literature, and newspaper/magazine searches:
  • Identifying various centers of specialization and articles that might provide leads for primary research

The secondary research stage builds the foundation for the primary research.

Step 1: The first step involves an impartial scan of all the information gathered during the secondary research stage to determine its utility based on the specific requirements of this report. Each piece of information is either discarded or marked as high- or low-priority and then organized appropriately as determined by the structure and sectioning of the report.

Step 2: At this stage, early assumptions are formed as to the implications of the information for the various orthopedic biomaterial market segments. These assumptions are then used to determine hypotheses using both inductive and deductive approaches. On the quantitative front, these hypotheses result in full historical and projected market data sets (market sizes - unit sales, average selling prices [ASPs], and revenues - as well as market shares).

Step 3: At this stage, the research is in position for its most important primary phase - expert interviews. Throughout the secondary research phase, industry and medical experts are identified.

These experts are then contacted by telephone and asked to participate in interviews on recent trends and developments in the industry. Interviews are either conducted at the time of the initial call or scheduled at the convenience of the expert. Interview questions are tailored to the expertise of each particular interviewee, although in most cases, the most important questions are asked of all experts.

The questions are largely based on the assumptions and hypotheses developed in Step 2, which are then augmented, discarded, or adjusted based on the views and positions put forth. Attempts are made, whenever possible, to cross-check the views of various experts against each other and to reach positions of consensus on issues and market numbers.

Step 4: The final stage of primary research involves individual and group analysis by Millennium Research Group. All research results are assessed and cross-checked thoroughly to determine their validity, relevance, and weight. From this process, qualitative conclusions are reached and data points finalized.

In addition to the research methodology outlined above, the following “bottom-up” methodology is used to develop forecast assumptions for the report.

A comprehensive breakdown of various orthopedic biomaterial procedures and unit sales is prepared using data from several sources, including professional associations, government statistics, and private research/media sources. Industry experts and practitioners are consulted to ensure accuracy and verify observed trends. As a cross-check, total industry revenues available through annual reports and other sources are compared against modeled industry revenues.

Using the best estimates of industry experts, practitioners, private research/media sources, and inhouse experts, year-by-year growth rates and ASPs are applied individually to each subcategory to derive forecasts. These estimates are cross-checked by industry experts (marketing managers, product managers, CEOs, etc.) and further refined.

Overall findings are compared against market and procedure forecasts published by other sources to ensure reasonable estimates.

Companies mentioned in this report:

• ACE Surgical Supply
• AlloSource
• Anika Therapeutics
• ApaTech (acquired by Baxter in 2010)
• Associated Medical Supplies
• AustSpine (acquired by LifeHealthcare)
• Baxter
• Bio Implant Technology
• Biomet
• BioMimetic Therapeutics
• Bioniche Pharma
• Cerapedics
• Chi-Fu Trading
• Chugai Pharmaceutical
• Covalent Materials
• Croma-Pharma
• DePuy
• Dongkwang Pharm
• Fidia Farmaceutici
• For-U Biopharma
• Fuji Pharmaceutical
• Geistlich
• Genzyme Biosurgery (acquired by Sanofi)
• Global Orthopaedic Technology
• GS Medical
• Hakusui Trading
• Hans Biomed
• Harvester Trading
• Henry Schein Halas
• Hisamitsu Pharmaceutical
• HUONS
• Integra LifeSciences
• Japan Medical Dynamic Marketing
• Japan Medical Materials
• Kaken Pharmaceutical
• Kensey Nash
• Kobayashi Pharmaceuticals
• Korea Bone Bank
• Kunming Baker Norton Pharmaceutical
• Kyungwon Medical
• LG Life Sciences
• LifeHealthcare
• Maruho
• Med Pharma
• Medtronic Spinal & Biologics
• Meiji Seika Pharma
• National Surgical Corporation
• NGK Spark Plug
• Nichi-Iko Pharmaceutical
• Nippon Zoki Pharmaceutical
• Nipro Pharma
• Nissin Pharmaceutical
• NuVasive
• Olympus Terumo Biomaterials
• Olympus Biotech
• Orthotech Orthopaedic Group
• Osteotech (acquired by Medtronic Spinal & Biologics in 2010)
• PENTAX
• Rottapharm - Madaus
• Sanofi
• Sawi Pharmaceutical
• Scient'x (acquired by Alphatec Spine)
• SciVision Biotech
• Seikagaku
• Shandong Bausch & Lomb Freda Pharmaceutical
• Shanghai Baijiayi Pharmaceutical
• Shanghai Haohai Bio-Tech
• Shin Poong Pharmaceutical
• Shiono Chemical
• Showa Ika Kohygo (acquired by Century Medical)
• Soelim International
• Stryker
• Surgical Synergies
• Synthes (to be acquired by Johnson & Johnson)
• Taiyo Yakuhin
• Takata Seiyaku
• TOWA Pharmaceutical
• TRB Chemedica
• Tsuruhara Pharmaceutical
• Uji Pharm
• Unimed
• Yoo Young Pharm
• Zimmer

TABLE OF CONTENTS

LIST OF FIGURES AND TABLES

EXECUTIVE SUMMARY

1.0. CLINICAL LANDSCAPE

• 1.1. Background
  • 1.1.1. Osteoarthritis
• 1.2. Procedure Overview
  • 1.2.1. Bone Graft Procedures
    • 1.2.1.1. Trauma Surgeries
    • 1.2.1.2. Large-Joint Revision and Reconstruction Procedures
    • 1.2.1.3. Thoracolumbar and Cervical Spinal Fusions
    • 1.2.1.4. Craniomaxillofacial Surgeries
    • 1.2.1.5. Extremity Surgeries
  • 1.2.2. Hyaluronic Acid Viscosupplementation Treatments
  • 1.2.3. Competing Treatments
  • 1.2.4. Emerging Competing Treatments and Technologies
• 1.3. Country Overview
  • 1.3.1. Australia
    • 1.3.1.1. Demographics and Economy
    • 1.3.1.2. Health Care System
    • 1.3.1.3. Regulatory Environment
    • 1.3.1.4. Manufacturing and Distribution
  • 1.3.2. Mainland China
    • 1.3.2.1. Demographics and Economy
    • 1.3.2.2. Health Care System
    • 1.3.2.3. Regulatory Environment
  • 1.3.3. Hong Kong
    • 1.3.3.1. Demographics and Economy
    • 1.3.3.2. Health Care System
  • 1.3.4. Japan
    • 1.3.4.1. Demographics and Economy
    • 1.3.4.2. Health Care System
    • 1.3.4.3. Regulatory Environment
    • 1.3.4.4. Manufacturing and Distribution
  • 1.3.5. South Korea
    • 1.3.5.1. Demographics and Economy
    • 1.3.5.2. Health Care System
    • 1.3.5.3. Regulatory Environment
    • 1.3.5.4. Manufacturing and Distribution
  • 1.3.6. Taiwan
    • 1.3.6.1. Demographics and Economy
    • 1.3.6.2. Health Care System

2.0. PRODUCTS

• 2.1. Overview
  • 2.1.1. Products Covered
• 2.2. Bone Grafts
  • 2.2.1. Functions
    • 2.2.1.1. Autografts
    • 2.2.1.2. Growth Factors
    • 2.2.1.3. Demineralized Bone Matrices
    • 2.2.1.4. Synthetics
    • 2.2.1.5. Nonproprietary Allografts
  • 2.2.2. Differentiating Features
  • 2.2.3. Emerging Products
• 2.3. Hyaluronic Acid Viscosupplementation Products
  • 2.3.1. Functions
  • 2.3.2. Differentiating Features
  • 2.3.3. Emerging Products

3.0. CLINICAL TRIALS

• 3.1. Completed Clinical Trials
• 3.2. Ongoing Clinical Trials

4.0. BRANDS AND COMPETITIVE ANALYSIS

• 4.1. Overview
  • 4.1.1. Competitive Snapshot
  • 4.1.2. Market Shares
  • 4.1.3. Recent Events
• 4.2. Bone Graft Substitute Market
  • 4.2.1. Competitive Snapshot
  • 4.2.2. Detailed Competitive Landscape
  • 4.2.3. Current Market Shares
• 4.3. Hyaluronic Acid Viscosupplementation Market
  • 4.3.1. Competitive Snapshot
  • 4.3.2. Detailed Competitive Landscape
  • 4.3.3. Current Market Shares

5.0. ORTHOPEDIC BIOMATERIAL MARKET OUTLOOK

• 5.1. Market Snapshot
• 5.2. Market Overview

6.0. BONE GRAFT SUBSTITUTE MARKET OUTLOOK

• 6.1. Market Snapshot
• 6.2. Detailed Market Overview
  • 6.2.1. Market Overview By Material
    • 6.2.1.1. Autografts (Procedures Only)
    • 6.2.1.2. Nonproprietary Allograft Market
    • 6.2.1.3. Synthetics Market
    • 6.2.1.4. Demineralized Bone Matrix Market
    • 6.2.1.5. Growth Factor Market
  • 6.2.2. Market Overview by Procedure Type
    • 6.2.2.1. Spinal Fusion Bone Graft Substitute Market
    • 6.2.2.2. Trauma Surgery Bone Graft Substitute Market
    • 6.2.2.3. Large-Joint Revision and Reconstruction Bone Graft Substitute Market
    • 6.2.2.4. Craniomaxillofacial Surgery Bone Graft Substitute Market
    • 6.2.2.5. Extremity Surgery Bone Graft Substitute Market
• 6.3. Australian Bone Graft Substitute Market Outlook
• 6.4. Japanese Bone Graft Substitute Market Outlook
• 6.5. South Korean Bone Graft Substitute Market Outlook

7.0. HYALURONIC ACID VISCOSUPPLEMENTATION MARKET OUTLOOK

• 7.1. Market Snapshot
• 7.2. Detailed Market Overview
• 7.3. Australian Hyaluronic Acid Viscosupplementation Market Outlook
• 7.4. Chinese Hyaluronic Acid Viscosupplementation Market Outlook
  • 7.4.1. Mainland Chinese Hyaluronic Acid Viscosupplementation Market Outlook
  • 7.4.2. Hong Kong Hyaluronic Acid Viscosupplementation Market Outlook
• 7.5. Japanese Hyaluronic Acid Viscosupplementation Market Outlook
• 7.6. South Korean Hyaluronic Acid Viscosupplementation Market Outlook
• 7.7. Taiwanese Hyaluronic Acid Viscosupplementation Market Outlook

APPENDIX A: METHODOLOGY

APPENDIX B: MRG ACRONYMS AND INITIALISMS

APPENDIX C: BIBLIOGRAPHY

TABLE OF CONTENTS

LIST OF FIGURES AND TABLES

EXECUTIVE SUMMARY

• Figure 1: Orthopedic Biomaterial Market, by Product Type, Asia Pacific (US$), 2010 - 2016
• Table 1: Orthopedic Biomaterial Market Landscape, Asia Pacific (US$), 2011 and 2016
• Table 2: Orthopedic Biomaterial Market Leaders, by Product Type, Asia Pacific, 2011
• Table 3: Most Promising Emerging Technologies in the Orthopedic Biomaterial Market, Asia Pacific, 2011 - 2016
• Table 4: Expected Key Events in the Orthopedic Biomaterial Market, Asia Pacific, 2012 - 2016
• Table 5: Factors Impacting the Orthopedic Biomaterial Market, by Product Type, Asia Pacific, 2011 - 2016
• Table 6: Companies Mentioned in This Report
• Table 7: Key Report Updates, 2012

1.0 CLINICAL LANDSCAPE

• Table 8: Key Health and Economic Indicators, Australia, 2011
• Table 9: Key Health and Economic Indicators, China, 2011
• Table 10: Key Health and Economic Indicators, Japan, 2011
• Table 11: Key Health and Economic Indicators, South Korea, 2011

2.0 PRODUCTS

• Table 12: Orthopedic Biomaterial Market, by Product Type, Asia Pacific
• Table 13: Characteristics of Bone Grafts, by Material
• Table 14: Select First-Generation Synthetic BGS Materials, by Material
• Table 15: Advantages and Disadvantages of Bone Grafts, by Material
• Table 16: Emerging Products for the BGS Market, Asia Pacific, 2011 - 2016
• Table 17: Advantages and Disadvantages of HA Viscosupplementation Products, by Number of Injections

3.0 CLINICAL TRIALS

• Table 18: Summary of Promoting Fusion in Minimally Invasive Lumbar Interbody Stabilization with Low-Dose BMP-2 - But What is the Cost?
• Table 19: Summary of SUPARTZ Versus Placebo in Osteoarthritis of the Shoulder Study
• Table 20: Summary of Three Injections of EUFLEXXA (Sodium Hyaluronate) for Treatment of Chronic Shoulder Pain Associated With Osteoarthritis (OA) Study
• Table 21: Summary of A Double-blind RCT of a Single Dose of Hyaluronan in the Treatment of Osteoarthritis of the Ankle
• Table 22: Summary of Efficacy of 3 Weekly Injections of Hyaluronate in Patients With Ankle Osteoarthritis
• Table 23: Summary of Efficacy of Three Weekly Injections of a Bacterial - Sourced Hyaluronate on Pain and Function in Patients With Knee Osteoarthritis (OA)
• Table 24: Summary of ORTHOVISC Shoulder RCT (OV Shoulder)
• Table 25: Summary of Comparative Analysis of Intra-articular Injection of Steroid and/or Sodium Hyaluronate in Adhesive Capsulitis
• Table 26: Efficacy and Safety of Accell Evo3 DBM in Instrumented Posterolateral Lumbar Spine Fusion
• Table 27: Summary of an Assessment of P-15 Bone Putty in Anterior Cervical Fusion With Instrumentation
• Table 28: Summary of APPRAISET1
• Table 29: Summary of INFUSE Bone Graft/PEEK Interbody Spacer/Anterior Cervical Plate Pivotal Clinical Trial (ACDF)

4.0 BRANDS AND COMPETITIVE ANALYSIS

• Table 30: Leading Competitors in the Orthopedic Biomaterial Market, by Product Type, as a % of Total, Asia Pacific, 2011
• Table 31: Recent Events in the Orthopedic Biomaterial Market, by Product Type, Asia Pacific
• Table 32: Leading Competitors in the BGS Market, as a % of Total, by Country, Asia Pacific, 2011
• Table 33: Leading Competitors in the HA Viscosupplementation Market, by Country, as a % of Total, Asia Pacific, 2011

5.0 ORTHOPEDIC BIOMATERIAL MARKET OUTLOOK

• Figure 2: Orthopedic Biomaterial Market Growth, by Product Type, Asia Pacific, 2011 - 2016
• Table 34: Factors Impacting the Orthopedic Biomaterial Market, by Product Type, Asia Pacific, 2011 - 2016
• Table 35: Orthopedic Biomaterial Market, by Product Type, Asia Pacific (US$), 2010 - 2016

6.0 BONE GRAFT SUBSTITUTE MARKET OUTLOOK

• Figure 3: BGS Market, by Material, Asia Pacific (US$), 2010 - 2016
• Table 36: Factors Impacting the BGS Market, Asia Pacific, 2011 - 2016
• Table 37: Bone Graft Procedures, by Country, Asia Pacific, 2010 - 2016
• Table 38: Bone Graft Procedures, by Material, Asia Pacific, 2010 - 2016
• Table 39: BGS Procedures, by Country, Asia Pacific, 2010 - 2016
• Table 40: BGS Procedures, by Procedure Type, Asia Pacific, 2010 - 2016
• Table 41: BGS Market, by Country, Asia Pacific (US$), 2010 - 2016
• Table 42: BGS Market, by Material, Asia Pacific (US$), 2010 - 2016
• Table 43: BGS Market, by Procedure Type, Asia Pacific (US$), 2010 - 2016
• Table 44: Bone Graft Procedures, by Material, Australia, 2010 - 2016
• Table 45: BGS Market, by Material, Australia (US$), 2010 - 2016
• Table 46: BGS Market, by Material, Australia (AU$), 2010 - 2016
• Table 47: BGS Market Growth, by Material, Australia, 2011 - 2016
• Table 48: BGS Market, by Material, as a % of Total, Australia, 2010 - 2016
• Table 49: BGS Market, by Procedure Type, Australia (US$), 2010 - 2016
• Table 50: BGS Market, by Procedure Type, Australia (AU$), 2010 - 2016
• Table 51: BGS Market Growth, by Procedure Type, Australia, 2011 - 2016
• Table 52: BGS Market, by Procedure Type, as a % of Total, Australia, 2010 - 2016
• Table 53: Bone Graft Procedures, by Material, Japan, 2010 - 2016
• Table 54: BGS Market, by Procedure Type, Japan (US$), 2010 - 2016
• Table 55: BGS Market, by Procedure Type, Japan (\), 2010 - 2016
• Table 56: BGS Market Growth, by Procedure Type, Japan, 2011 - 2016
• Table 57: BGS Market, by Procedure Type, as a % of Total, Japan, 2010 - 2016
• Table 58: Bone Graft Procedures, by Material, South Korea, 2010 - 2016
• Table 59: BGS Market, by Material, South Korea (US$), 2010 - 2016
• Table 60: BGS Market, by Material, South Korea (KRW), 2010 - 2016
• Table 61: BGS Market Growth, by Material, South Korea, 2011 - 2016
• Table 62: BGS Market, by Material, as a % of Total, South Korea, 2010 - 2016
• Table 63: BGS Market, by Procedure Type, South Korea (US$), 2010 - 2016
• Table 64: BGS Market, by Procedure Type, South Korea (KRW), 2010 - 2016
• Table 65: BGS Market Growth, by Procedure Type, South Korea, 2011 - 2016
• Table 66: BGS Market, by Procedure Type, as a % of Total, South Korea, 2010 - 2016

7.0 HYALURONIC ACID VISCOSUPPLEMENTATION MARKET OUTLOOK

• Figure 4: HA Viscosupplementation Market, by Country, Asia Pacific (US$), 2010 - 2016
• Table 67: Factors Impacting the HA Viscosupplementation Market, Asia Pacific, 2011 - 2016
• Table 68: HA Viscosupplementation Treatments, by Country, Asia Pacific, 2010 - 2016
• Table 69: HA Viscosupplementation Treatments and Injections, by Number of Injections, Asia Pacific, 2010 - 2016
• Table 70: HA Viscosupplementation Treatments, by Anatomy, Asia Pacific, 2010 - 2016
• Table 71: HA Viscosupplementation Market, by Country, Asia Pacific (US$), 2010 - 2016
• Table 72: HA Viscosupplementation Market, by Number of Injections, Asia Pacific (US$), 2010 - 2016
• Table 73: HA Viscosupplementation Market Growth, by Number of Injections, Asia Pacific, 2011 - 2016
• Table 74: HA Viscosupplementation Market, by Number of Injections, as a % of Total, Asia Pacific, 2010 - 2016
• Table 75: HA Viscosupplementation Treatments and Injections, by Number of Injections, Australia, 2010 - 2016
• Table 76: HA Viscosupplementation Treatments, by Anatomy, Australia, 2010 - 2016
• Table 77: HA Viscosupplementation Market, by Number of Injections, Australia (US$), 2010 - 2016
• Table 78: HA Viscosupplementation Market, by Number of Injections, Australia (AU$), 2010 - 2016
• Table 79: HA Viscosupplementation Market Growth, by Number of Injections, Australia, 2011 - 2016
• Table 80: HA Viscosupplementation Market, by Number of Injections, as a % of Total, Australia, 2010 - 2016
• Table 81: HA Viscosupplementation Treatments, Mainland China and Hong Kong, 2010 - 2016
• Table 82: HA Viscosupplementation Treatments and Injections, by Number of Injections, Mainland China, 2010 - 2016
• Table 83: HA Viscosupplementation Treatments, by Anatomy, Mainland China, 2010 - 2016
• Table 84: HA Viscosupplementation Market, Mainland China and Hong Kong (US$), 2010 - 2016
• Table 85: HA Viscosupplementation Market, by Number of Injections, Mainland China (US$), 2010 - 2016
• Table 86: HA Viscosupplementation Market, by Number of Injections, Mainland China (CNY), 2010 - 2016
• Table 87: HA Viscosupplementation Market Growth, by Number of Injections, Mainland China, 2011 - 2016
• Table 88: HA Viscosupplementation Market, by Number of Injections, as a % of Total, Mainland China, 2010 - 2016
• Table 89: HA Viscosupplementation Treatments and Injections, by Number of Injections, Japan, 2010 - 2016
• Table 90: HA Viscosupplementation Treatments, by Anatomy, Japan, 2010 - 2016
• Table 91: HA Viscosupplementation Treatments, by Product Type, Japan, 2010 - 2016
• Table 92: HA Viscosupplementation Market, by Number of Injections, Japan (US$), 2010 - 2016
• Table 93: HA Viscosupplementation Market, by Number of Injections, Japan (\), 2010 - 2016
• Table 94: HA Viscosupplementation Market Growth, by Number of Injections, Japan, 2011 - 2016
• Table 95: HA Viscosupplementation Market, by Number of Injections, as a % of Total, Japan, 2010 - 2016
• Table 96: HA Viscosupplementation Market, by Product Type, Japan (US$), 2010 - 2016
• Table 97: HA Viscosupplementation Market, by Product Type, Japan (\), 2010 - 2016
• Table 98: HA Viscosupplementation Market Growth, by Product Type, Japan, 2011 - 2016
• Table 99: HA Viscosupplementation Market, by Product Type, as a % of Total, Japan, 2010 - 2016
• Table 100: HA Viscosupplementation Treatments and Injections, by Number of Injections, South Korea, 2010 - 2016
• Table 101: HA Viscosupplementation Treatments, by Anatomy, South Korea, 2010 - 2016
• Table 102: HA Viscosupplementation Market, by Number of Injections, South Korea (US$), 2010 - 2016
• Table 103: HA Viscosupplementation Market, by Number of Injections, South Korea (KRW), 2010 - 2016
• Table 104: HA Viscosupplementation Market Growth, by Number of Injections, South Korea, 2011 - 2016
• Table 105: HA Viscosupplementation Market, by Number of Injections, as a % of Total, South Korea, 2010 - 2016
• Table 106: HA Viscosupplementation Treatments and Injections, by Number of Injections, Taiwan, 2010 - 2016
• Table 107: HA Viscosupplementation Treatments, by Anatomy, Taiwan, 2010 - 2016
• Table 108: HA Viscosupplementation Market, by Number of Injections, Taiwan (US$), 2010 - 2016
• Table 109: HA Viscosupplementation Market, by Number of Injections, Taiwan (TW$), 2010 - 2016
• Table 110: HA Viscosupplementation Market Growth, by Number of Injections, Taiwan, 2011 - 2016
• Table 111: HA Viscosupplementation Market, by Number of Injections, as a % of Total, Taiwan, 2010 - 2016

APPENDIX A: METHODOLOGY

• Table 112: Average Currency Exchange Rates, 2011

APPENDIX B: MRG ACRONYMS AND INITIALISMS

• MRG Acronyms and Initialisms

APPENDIX C: BIBLIOGRAPHY

相關商品

生物材料相關市場調查報告書

口腔清潔用品&牙科用消耗品市場(牙科生技材料·特殊用途產品·修復劑):目前趨勢·市場機會·全球市場預測(∼2016年)
Oral Care Products & Other Dental Consumables Market (Dental Biomaterials, Specialty Products, & Restoratives) Current Trends, Opportunities & Global Forecasts to 2016
價格 : US $ 4650
出版日期 : 2012年04月

歐洲的牙科用人工骨替代材料，牙科再生膜及再生牙科市場(21個國家):2012年
European Markets for Dental Bone Graft Substitutes, Dental Membranes and Tissue Engineering 2012 (21 countries)
價格 : US $ 10995
出版日期 : 2012年03月

生物相容性材料的全球市場
Biocompatible Materials
價格 : US $ 4500
出版日期 : 2012年02月

Millennium Research Group發行的生物科技相關市場調查報告書

歐洲的整形外科用軟組織解決方案市場:2012年

European Markets for Orthopedic Soft Tissue Solutions 2012

價格 : US $ 5995

出版日期 : 2012年03月

歐洲的整形外科生醫材料市場:2012年

European Markets for Orthopedic Biomaterials 2012

價格 : US $ 6995

出版日期 : 2011年12月

美國的外科用止血劑·組織內密封材料·防粘黏薄膜市場:2012年

US Markets for Surgical Hemostats, Internal Tissue Sealants, and Adhesion Barriers 2012

價格 : US $ 6995

出版日期 : 2011年11月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!